



MD MEDICAL GROUP COMPLETES ACQUISITION OF FOUR CLINICS IN KHANTY-MANSI AUTONOMOUS AREA–YUGRA

19 September 2023 – MD Medical Group (“MD Medical Group”, “the Group” or “the Company”; MOEX: MDMG), a leader of Russia's private medical services market, announces that it has completed the acquisition of four clinics in the Khanty-Mansi Autonomous Area–Yugra.

Following the acquisition, the Group will take a leading position in private medicine in the area and create an outpatient base for referring patients to the Group's hospital in Tyumen for high-tech services. The total cost of the deal is RUB 349 million paid from the Group's own funds.

With a population of 1.7 million, the Khanty-Mansi Autonomous Area is the second largest economy in Russia (after Moscow). Due to its economic performance, the region is of strategic interest for the Group's expansion.

Biomeditsina Diagnostic and Treatment Centre is one of the leading clinics in Surgut with an area of 949 sq m. It provides a full range of outpatient services with MRI diagnostics and can handle up to 99,000 visits per year. The Group acquires 100% of the centre.

Antireflux-Biomed is the leader in the treatment of phlebological diseases in Surgut. With an area of 200 sq m, the clinic can handle up to 18,000 visits per year. The Group acquires 75% of the clinic.

Vira-Centre is the first and largest private medical company in Nefteyugansk. Having operated for 27 years, it is currently represented by two clinics with a total area of 832 sq m. The company provides a full range of polyclinic services and has a laboratory of its own. The clinics' traffic is around 84,000 visits per year. The Group acquires 100% of the company.

Mark Kurtser, CEO at MDMG, said:

"The deal is a logical continuation of the Group's expansion into promising and new regions. The Khanty-Mansi Autonomous Area is Russia's leading region in terms of economic development and the 27th region in our geography. Our own competences, including those related to women's health and IVF, will contribute to the region's welfare. MD Medical Group's high quality standards of medical care and professional team of doctors in the clinics will allow us to increase the volume of healthcare and lead in the region. We will also be able to refer patients to our hospital in Tyumen for high-tech care, which will be an additional growth driver for the hospital."

Notes:

1. This announcement contains inside information



MD Medical

GROUP OF COMPANIES

For further information please contact:

Investors

Investor Relations Department

Tel.: +7 (495) 139-87-40 (ext: 16345)

ir@mcclinics.ru

About MD Medical Group

MD Medical Group is a leading provider in the highly attractive Russian private healthcare service market. Today, the Company manages 53 state-of-the-art healthcare facilities, including 10 multidisciplinary hospitals and 43 out-patient clinics in 27 regions of the Russian Federation. In 2022, MD Medical Group's revenue amounted to RUB 25.2 bln while EBITDA amounted to RUB 7.9 bln. The Company's GDRs are traded on Moscow Exchange (MOEX: MDMG).

Forward-Looking Statements

This press release contains forward-looking statements, which are based on the Company's current expectations and assumptions and may involve known and unknown risks and uncertainties that could cause actual results, performance or events to differ materially from those expressed or implied in such statements. The forward-looking statements contained in this press release are based on past trends or activities and should not be taken that such trends or activities will continue in the future. It is believed that the expectations reflected in these statements are reasonable, but they may be affected by a number of variables which could cause actual results or trends to differ materially, including, but not limited to: conditions in the market, market position of the Company, earnings, financial position, cash flows, return on capital and operating margins, anticipated investments and economic conditions; the Company's ability to obtain capital/additional finance; a reduction in demand by customers; an increase in competition; an unexpected decline in revenue or profitability; legislative, fiscal and regulatory developments, including, but not limited to, changes in environmental and health and safety regulations; exchange rate fluctuations; retention of senior management; the maintenance of labour relations; fluctuations in the cost of input costs; and operating and financial restrictions as a result of financing arrangements. No statement in this press release is intended to constitute a profit forecast, nor should any statements be interpreted to mean that earnings or earnings per share will necessarily be greater or lesser than those for the relevant preceding financial periods for the Company. Each forward-looking statement relates only as of the date of the particular statement.